Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors.

Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge

Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423

Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia

Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881

The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in Incidence of Coronary Heart Disease

(1984) · JAMA · doi:10.1001/jama.1984.03340270029025 · Cited by 2,747

Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions

Burstein, M., Scholnick, H. R., & Morfin, R. F. (1970) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42943-8 · Cited by 2,500

Apolipoprotein E polymorphism and atherosclerosis.

Davignon, J., Gregg, R. E., & Sing, C. F. (1988) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.8.1.1 · Cited by 1,981

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824

Atherogenesis: a postprandial phenomenon.

Zilversmit, D. B. (1979) · Circulation · doi:10.1161/01.cir.60.3.473 · Cited by 1,701

Beneficial Effects of Combined Colestipol-Niacin Therapy on Coronary Atherosclerosis and Coronary Venous Bypass Grafts

Blankenhorn, D. H. (1987) · JAMA · doi:10.1001/jama.1987.03390230069027 · Cited by 1,654

Sur un dosage rapide du cholesterol lié aux α-et aux β-lipoprotéines du sérum

Burstein, M., & Samaille, J. (1960) · Clinica Chimica Acta · doi:10.1016/0009-8981(60)90075-9 · Cited by 620

Diet, Lipoproteins, and the Progression of Coronary Atherosclerosis

Arntzenius, A. C., Kromhout, D., Barth, J. D., Reiber, J. H. C., Bruschke, A. V. G., Buis, B., van Gent, C. M., Kempen-Voogd, N., Strikwerda, S., & van der Velde, E. A. (1985) · New England Journal of Medicine · doi:10.1056/nejm198503283121301 · Cited by 498

The Importance of Non High Density Lipoprotein Cholesterol in Dyslipidaemia Management

Chowdhury, S., & Chowdhury, J. R. (2015) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000623 · Cited by 9

Remnant-like lipoproteins, hormone therapy, and angiographic and clinical outcomes: The Women's Angiographic Vitamin & Estrogen trial

Bittner, V., Tripputi, M., Hsia, J. A., Gupta, H., & Steffes, M. W. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.01.025 · Cited by 9

Hypertriglyceridemia and Cardiovascular Outcomes

Malhotra, G., Sethi, A., & Arora, R. R. (2014) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000116 · Cited by 9

Apolipoprotein A-1 and apolipoprotein B containing lipoprotein particles in coronary patients treated with extracorporal low density lipoprotein precipitation (HELP)

Koren, E., Armstrong, V. W., Müller, G., Wilson, P. R., Schuff‐Werner, P., Thiery, J., Eisenhauer, T., Alaupovic, P., & Seidel, D. (1992) · Atherosclerosis · doi:10.1016/0021-9150(92)90019-d · Cited by 9

Recomendaciones prácticas para el manejo del riesgo cardiovascular asociado a la dislipemia aterogénica, con especial atención al riesgo residual. Adaptación española de un Consenso Europeo de Expertos

de Expertos, G. D. T. D. D. A. D. L. S. E. D. A. Y. G. E. (2017) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2016.12.001 · Cited by 8

Apolipoprotein-defined lipoprotein subclasses, serum apolipoproteins, and carotid intima-media thickness in T1D

Basu, A., Jenkins, A. J., Stoner, J. A., Zhang, Y., Klein, R. L., Lopes-Virella, M. F., Garvey, W. T., Schade, D. S., Wood, J., Alaupovic, P., et al. (2018) · Journal of Lipid Research · doi:10.1194/jlr.p080143 · Cited by 8

A new look at coronary angiograms: plaque morphology as a help to diagnosis and to evaluate outcome

Lesp�rance, J., Th�roux, P., Hudon, G., & Waters, D. D. (1994) · International journal of cardiac imaging · doi:10.1007/bf01137703 · Cited by 8

Distribution of CII and CIII peptides in lipoprotein classes: methods and clinical significance

Graziani, M. S., Zanolla, L., Righetti, G., Marchetti, C., Zanotto, G., & Lupo, A. (1994) · Clinical Chemistry · doi:10.1093/clinchem/40.2.240 · Cited by 8

Use of Apolipoprotein Parameters and Endpoints in Drug Development and Approval Processes

Alaupovic, P. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00260-4 · Cited by 7

Evaluation of new apolipoprotein C-II and apolipoprotein C-III automatized immunoturbidimetric kits

Nicolay, A., Lombard, E., Arlotto, E., Saunier, V., Lorec, A., Lairon, D., & Portugal, H. (2006) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2006.04.021 · Cited by 7

Frequency of citation and outcome of cholesterol lowering trials.

Durrington, P., Laker, M., & Keech, A. (1992) · British medical journal · doi:10.1136/bmj.305.6850.420-d · Cited by 5

Petar Alaupovic

Sacks, F. M., & Brewer, H. B. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.303500 · Cited by 7

Myocardial Ischemia and Lipoprotein Lipase Activity

Hodis, H. N. (2000) · Circulation · doi:10.1161/01.cir.102.14.1600 · Cited by 7

Atherosclerosis progression/regression: lipoprotein and vessel wall determinants

Krarnsch, D. M. (1995) · Atherosclerosis · doi:10.1016/0021-9150(95)90070-5 · Cited by 6

Triglycerides and Cardiovascular Disease : A Scientific Statement From the

Pennathur, S., Kris‐Etherton, P. M., Lennie, T. A., Levi, M., Mazzone, T., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Stone, N. J., Ballantyne, C. M., et al. (2011) · Cited by 6

Preventing, stopping, or reversing coronary artery disease— triglyceride-rich lipoproteins and associated lipoprotein and metabolic abnormalities: The need for recognition and treatment

Ferguson, E. E. (2000) · Disease-a-Month · doi:10.1016/s0011-5029(00)90011-7 · Cited by 6

Therapeutic intervention for hypercholesterolemia

Gotto, A. M. (1992) · Clinical Cardiology · doi:10.1002/clc.4960151007 · Cited by 6

Genesis of Atherosclerosis in Uremic Patients

Drüeke, T. B. (1999) · Mineral and Electrolyte Metabolism · doi:10.1159/000057456 · Cited by 6

Efficacy of interventions designed to inhibit the progression of coronary atherosclerosis

Macka, W. J., & Hodis, H. N. (1996) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(96)80037-4 · Cited by 6

Secondary Prevention of Coronary Heart Disease in Patients with Extracoronary Atherosclerosis: A Need for Accuracy of Low Density Lipoprotein Determination

Sentı́, M., Pedro‐Botet, J., Rubiés-Prat, J., & Vidal-Barraquer, F. (1996) · Angiology · doi:10.1177/000331979604700304 · Cited by 5

Lipids and Lipid-Lowering Drugs and Graft Function

Drexel, H., & Amann, F. W. (1994) · Springer eBooks · doi:10.1007/978-3-642-78637-2_15 · Cited by 5

Triglyceride-Rich Lipoproteins

Le, N., & Brown, W. V. (2010) · Springer eBooks · doi:10.1007/978-1-4419-5839-6_4 · Cited by 5

The independent roles of diet and serum lipids in the 20th-century rise and decline of coronary heart disease mortality

Rosenman, R. H. (1993) · Integrative Psychological and Behavioral Science · doi:10.1007/bf02691202 · Cited by 4

Apolipoprotein A and prognosis after myocardial infarction in non-diabetic men

Pollak, H., Arnoldner, O., Enenkel, W., Fischer, M., & Trubert-Exinger, D. (1991) · Journal of Molecular Medicine · doi:10.1007/bf01649048 · Cited by 4

Cardiovascular Therapies in the 1990s

Becker, R. C., & Gore, J. M. (1991) · Drugs · doi:10.2165/00003495-199141030-00003 · Cited by 4

Lipoprotein Abnormalities in Patients with Atherosclerotic Renovascular Disease

Nowakowska-Fortuna, E., Herlitz, H., Saeed, A., Attman, P., Jensen, G., Alaupovic, P., & Guron, G. (2011) · Kidney & Blood Pressure Research · doi:10.1159/000325648 · Cited by 3

Practical recommendations for the management of cardiovascular risk associated with atherogenic dyslipidemia, with special attention to residual risk. Spanish adaptation of a European Consensus of Experts

Atherogenic Dyslipemia Working Group of the Spanish Society of Atherosclerosis and the European Expert Group (2017) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2017.07.002 · Cited by 3

Lipid Risk Factors and the Regression of Atherosclerosis

Gotto, A. M. (1995) · Medical science symposia series · doi:10.1007/978-94-011-0039-7_1 · Cited by 3

Blood Lipid and Lipoprotein Concentrations in Active, Sedentary, Healthy and Diseased Men

Bailey, D. M., Davies, B., Williams, S., & Baker, J. S. (1998) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/174182679800500504 · Cited by 3

On the atherogenicity of triglyceride-rich lipoproteins and novel markers for the assessment of their atherogenic potentials

Alaupovic, P. (2002) · Oléagineux Corps gras Lipides · doi:10.1051/ocl.2002.0220 · Cited by 3

Intermediate-Density Lipoprotein Is a DNA Synthesis Stimulation Factor in Cultured Human Mesangial Cells

Nomura, S., Sasaki, T., Kitano, Y., Osawa, G., Niederstadt, C., Lerche, L., & Steinhoff, J. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000189072 · Cited by 3

Niacin: A therapeutic dilemma “one man's drink is another's poison”

Kreisberg, R. A. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90296-8 · Cited by 3

Apolipoprotein C-III Bound to Apolipoprotein B-containing Lipoproteins in Obese Girls

Blackett, P. R., Germany, R. E., Sambo, B. H., & Alaupovic, P. (2003) · Clinical Chemistry · doi:10.1373/49.2.303 · Cited by 3

Management of dyslipidemia after coronary artery bypass grafting

Alaupovic, P. (2000) · Current Opinion in Lipidology · doi:10.1097/00041433-200008000-00005 · Cited by 3

Electroimmunoassay and Enzyme Linked Immunosorbent Assay for Quantitative Determination of Plasma Apolipoproteins

Koren, E., & Alaupovic, P. (1993) · AOCS Publishing eBooks · doi:10.1201/9781439831960.ch8 · Cited by 3

Lipid Lowering Therapy

Smith, D. A. (1999) · Developments in cardiovascular medicine · doi:10.1007/978-1-4615-5007-5_4 · Cited by 3

Dysapolipoproteinaemia Influences the Relationship Between Very Low-Density Lipoprotein Cholesterol and Intra-Pancreatic Fat Deposition in Humans

Liu, Y., Skudder‐Hill, L., Ko, J., Shamaitijiang, X., Sequeira, I. R., & Petrov, M. S. (2025) · Nutrients · doi:10.3390/nu17233718 · Cited by 2

Elevated levels of apolipoprotein C3 impair platelet function and reduce thrombosis

Schrottmaier, W. C., Kral-Pointner, J. B., Mußbacher, M., Salzmann, M., Hochreiter, B., Pirabe, A., Reiter, T., Badrnya, S., Schmid, J. A., Volf, I., et al. (2026) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2026.01.004 · Cited by 2

Relationship of HDL Cholesterol to Incidence of Atherosclerotic Coronary Heart Disease: The Procam Experience

von Eckardstein, A., Assmann, G., & Schulte, H. (1993) · Medical science symposia series · doi:10.1007/978-94-011-1703-6_42 · Cited by 2

Evaluación de la heterogeneidad y función de HDL por el laboratorio

Movva, R., & Rader, D. J. (2009) · Redalyc (Universidad Autónoma del Estado de México) · Cited by 2

Visceral Adiposity and Apolipoprotein C-III in Apolipoprotein B-Containing Lipoproteins Are Independent Predictors in Determining Atherogenic Lipid Profiles

Han, T., Woo, S.-K., Shin, S., & Kang, H. (2005) · Annals of Nutrition and Metabolism · doi:10.1159/000089562 · Cited by 2

Atherogenicity of Triglyceride-Rich Lipoproteins

Tallis, G. A. (1994) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/174182679400100303 · Cited by 2

Pharmacologic Prevention of Restenosis Following Angioplasty

Jäger, K., Frauchiger, B., & EICHLISBERGER, R. (1993) · Springer eBooks · doi:10.1007/978-3-662-01654-1_22 · Cited by 2

Residual Risk Reduction Initiative: výzva ke snížení reziduálního vaskulárního rizika u pacientů s dyslipidemií

Fruchart, J., Sacks, F. M., Hermans, M. P., Assmann, G., Brown, W. V., Češka, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2010) · Cor et Vasa · doi:10.33678/cor.2010.056 · Cited by 1

Contribución de la apolipoproteína CIII a la aterogenicidad de las dislipidemias

Camejo, G., & Davidsson, P. (2012) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2012.02.006 · Cited by 1

Síndrome de ovarios poliquísticos: hiperinsulinemia relacionada con riesgo cardiovascular

Tejerizo-López, L. C., Tejerizo-García, A., Sánchez-Sánchez, M. M., García-Robles, R. M., Leiva, A., Morán, E., Corredera, F., Pérez-Escanilla, J. A., & Benavente, J. M. (2001) · Clínica e Investigación en Ginecología y Obstetricia · doi:10.1016/s0210-573x(01)77088-8 · Cited by 1

The effects of exercise on primary and secondary coronary heart disease

Davies, B. (1997) · Coronary Health Care · doi:10.1016/s1362-3265(97)80717-1 · Cited by 1

Reversal of Atherosclerosis with Therapy: Update of Coronary Angiographic Trials

Hodis, H. N. (1996) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60279-3 · Cited by 1

Lipid and apolipoprotein levels during therapy with pinacidil combined with hydrochlorothiazide

Corder, C. N., Goldberg, M. R., Alaupovic, P., Price, M. D., & Furste, S. S. (1992) · European Journal of Clinical Pharmacology · doi:10.1007/bf00314922 · Cited by 1

Distribution of immunochemically defined apoB-containing lipoprotein subclasses in T1D

Bagdade, J. D., Knight‐Gibson, C., Quiroga, C., Jacobson, M., & Lee, D. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.06.012 · Cited by 1

Frequency of citation and outcome of cholesterol lowering trials.

Game, F., & Neary, R. (1992) · British medical journal · doi:10.1136/bmj.305.6850.421-a · Cited by 2

Cholesterol-Lowering Clinical Trials: Where Do We Go From Here?

Gotto, A. M. (1992) · The Argenteuil symposia · doi:10.1007/978-1-4471-1909-8_16

Rationale to Treat

Blankenhorn, D. H., & Hodis, H. N. (1994) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-78426-2_8

Diagnostics of Lipids and Lipoproteins

Wieland, H., März, W., & Nauck, M. (1994) · Springer eBooks · doi:10.1007/978-3-642-78959-5_3

Statin therapy in diabetic dyslipidemia : efficacy and mechanisms

Berk-Planken, I. I. L. (2003) · RePub (Erasmus University Rotterdam)

Frequency of citation and outcome of cholesterol lowering trials.

Anderson, J. (1992) · British medical journal · doi:10.1136/bmj.305.6850.421-b

Plasma lipoprotein alterations in patients with chronic hepatocellular liver disease re sulting from alcohol abuse: effects of alcohol intake cessa tion

McMillen, B. A. (1996) · Alcohol · doi:10.1016/s0741-8329(96)90015-4

Frequency of citation and outcome of cholesterol lowering trials.

Goodwin, J. (1992) · British medical journal · doi:10.1136/bmj.305.6850.421 · Cited by 6

TABLE RONDE Première partie : L’apolipoprotéine CIII marqueur d’anomalies métaboliques liées au risque de maladies cardiovasculaires

Combe, N., Delplanque, B., Fossati, P., Mendy, F., & Alaupovic, P. (2002) · Oléagineux Corps gras Lipides · doi:10.1051/ocl.2002.0253

Altered metabolism of apolipoprotein C.III: a contributor in chronic kidney disease?

Ooi, E. M. M., Watts, G. F., & Barrett, P. H. R. (2011) · Clinical Lipidology · doi:10.2217/clp.11.18

Medikamentöse und diätetische Therapie der Hyperlipidämie im Kindesalter: Evaluation von Wirksamkeit, Nebenwirkungen und Compliance im Patientenkollektiv der Kinder-Lipidambulanz von 1997-2000

Brümmer, S. M. (2002)

Role Of Lipid Concentrations and Apolipoproteins In Altering ApoB Metabolism and Promoting Coronary Events

Sacks, F. M. (2000) · Springer eBooks · doi:10.1007/978-4-431-68424-4_2

Apolipoprotein C-III, An Important Player in Lipoprotein Metabolism

Fruchart, J., Barthelemy-Clavey, V., Luc, G., Dallongeville, J., Staels, B., & Auwerx, J. H. (1996) · Medical science symposia series · doi:10.1007/978-94-009-0311-1_74

RT-PCR für LDL-Rezeptor-mRNA aus Lymphozyten von Patienten mit Familiärer und Polygener Hypercholesterinämie

Greten, H. (2001)

Drugs Affecting High-Density Lipoprotein and Triglyceride Metabolism

Gotto, A. M. (1993) · Medical science symposia series · doi:10.1007/978-94-011-1703-6_27

Triglycerides and Cardiovascular Disease: A Scientific Statement From the American

Lennie, T. A., Levi, M., Mazzone, T., Pennathur, S., Goldberg, A. C., Howard, W. J., Jacobson, M. Z., Stone, N. J., Ballantyne, C. M., Bittner, V., et al. (2013)

Lipid Management and Graft Failure

Daida, H., & Inaba, H. (2016) · Springer eBooks · doi:10.1007/978-3-319-26515-5_30

Key Differences Between Hepatic and Intestinal apoC3 Regulation and Expression, and Implications for Cardiovascular Disease Risk

West, G. (2017) · OpenCommons - UConn (University of Connecticut)

Risk Factors

Le, N., & Brown, W. V. (2007) · Humana Press eBooks · doi:10.1007/978-1-59259-878-6_28

Epidemiology

Kontush, A., & Chapman, M. J. (2011) · Wiley eBooks · doi:10.1002/9781118158678.ch5

Triglyceride-Rich Lipoproteins

Le, N., & Brown, W. V. (2000) · doi:10.1007/978-1-4757-9310-9_5

Triglyceride-Rich Lipoproteins

Le, N., & Brown, W. V. (2003) · doi:10.1007/978-1-4615-6484-3_5

Hypertriglycéridémie

Labrousse, F. (2002) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(02)00046-x

The use of metabolic measurements in angiographic regression trials

Watts, G. F. (1996) · Developments in cardiovascular medicine · doi:10.1007/978-94-009-0143-8_3

Lipoprotein lipase.

Connelly, P. W. (1990) · Europe PMC (PubMed Central)

Increased Triglyceride Levels and Cardiovascular Disease

Gotto, A. M. (1992) · Medical science symposia series · doi:10.1007/978-94-011-2700-4_28

FIGURES 71‒72 in Early-diverging bumblebees from across the roof of the world: the high-mountain subgenus Mendacibombus revised from species' gene coalescents and morphology (Hymenoptera, Apidae)

Williams, P. H., Huang, J., Rasmont, P., & An, J. (2016) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.192318

Lessons from the Monitored Atherosclerosis Regression Study (MARS) and beyond: atherosclerosis progression/regression responses to therapy depend on lesion size and composition

Kramsch, D. M. (1996) · Developments in cardiovascular medicine · doi:10.1007/978-94-009-0143-8_12

Prediction of Angiographic Change in Native Human Coronary Arteries and Aortocoronary Bypass Grafts Lipid and Nonlipid

Hp, C., & Azen, S. P. (2016)

Beneficial Effects of Combined Colestipol-Niacin Therapy on Coronary Atherosclerosis and Coronary Venous Bypass Grafts

Blankenhorn, D. H. (1987) · JAMA · doi:10.1001/jama.1987.03390230069027 · Cited by 1,654

Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin.

Hodis, H. N., Mack, W. J., Azen, S. P., Alaupovic, P., Pogoda, J. M., LaBree, L., Hemphill, L., Kramsch, D. M., & Blankenhorn, D. H. (1994) · Circulation · doi:10.1161/01.cir.90.1.42 · Cited by 321

Associations Between Lipoproteins and the Progression of Coronary and Vein-Graft Atherosclerosis in a Controlled Trial With Gemfibrozil in Men With Low Baseline Levels of HDL Cholesterol

Syvänne, M., Nieminen, M. S., Frick, M. H., Kauma, H., Majahalme, S. K., Virtanen, V., Kesäniemi, Y. A., Pasternack, A. I., Ehnholm, C., & Taskinen, M. (1998) · Circulation · doi:10.1161/01.cir.98.19.1993 · Cited by 67

The Relation of Risk Factors to the Development of Atherosclerosis in Saphenous-Vein Bypass Grafts and the Progression of Disease in the Native Circulation

CAMPEAU, L. A., Enjalbert, M., Lespérance, J., Bourassa, M. G., Kwiterovich, P. O., Wacholder, S., & Sniderman, A. D. (1984) · New England Journal of Medicine · doi:10.1056/nejm198411223112101 · Cited by 621